UNSPSC 51142526: Ethopropazine or profenamine

This classification denotes an antiparkinsonian agent with the molecular formula C19H24N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WI4P02YN1, chemically known as 10h-phenothiazine-10-ethanamine, n,n-diethyl-.alpha.-methyl-, monohydrochloride but generally known as ethopropazine, which bears US NIH Compound Identifier 3290. European Medicines Agency schedules Profenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10071MIG. The term ETHOPROPAZINE is an International Non-Proprietary Name.

World Health Organization schedules ethopropazine in its Anatomical Therapeutic Chemical (ATC) Classification. Ethopropazine or profenamine bears US NLM identifiers UMLS ID C0015042 and NCI Concept Code C73333. SMILES: CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31.

UNSPSC 51142526 Ethopropazine or profenamine, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity posted under it. The code's title refers to a specific antipsychotic or antihistamine pharmaceutical ingredient, yet the three recent opportunities tagged to it span naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical and OTC product contracting — none of which involve ethopropazine or profenamine specifically. State and local health agencies, cooperative purchasing alliances, and human services commissions are using this code to solicit pharmaceuticals broadly, suggesting either a tagging error in the underlying procurement system or a code applied as a catch-all for pharmaceutical procurement that does not match its Commodity-level specificity. The mismatch limits the code's utility as a predictor of demand for the actual active ingredient.

The three posted opportunities originate from distinct issuing bodies: Seminole County, Florida (an IFB for naloxone and drug deactivation systems, due July 26, 2023, requiring 1,900 units of naloxone and 800 deactivation systems annually); the Texas Health and Human Services Commission (an RFI on direct-to-manufacturer prescription fulfillment, posted April 3, 2026, to inform future contracting strategy); and the Minnesota Multistate Cooperative Purchasing Alliance (an RFP for generic pharmaceuticals and OTC products across participating state and local facilities, due March 26, 2026, with award effective July 1, 2026). Activity spans Florida, Texas, and Minnesota with multi-state reach through the cooperative vehicle. Vendors pursuing actual pharmaceutical ingredients or formulations should confirm the correct UNSPSC code with the issuing body before investing in proposal development, as this code does not reliably signal procurement demand for ethopropazine or profenamine.